FDA
-
-
-
-
-
-
-
Seaport Therapeutics appoints Dr. Sharon Mates to board of directors
-
-
-
-
-
-
-
EIB Waives its Right to Cash Settlement on Medincell Warrants
-
-
-
-
-
-
-
Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizo
-
-
-
-
-
-
-
Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 9, 2025
-
-
-
-
-
-
-
Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York)
-
-
-
-
-
-
-
Medincell: New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed
-
-
-
-
-
-
-
UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025
-
324,879 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

